CAMBRIDGE, United Kingdom & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, announced today that the company will present preclinical data supporting the ongoing development of its lead molecule, BT1718. This program is the first example of its Bicycle Drug Conjugate® technology, which allows toxic payloads to be targeted to tumour types of high unmet medical need. BT1718 targets Type 1 Matrix Metalloproteinase (MT1-MTP), which is highly expressed in many solid tumours, including triple negative breast cancer and non-small cell lung cancer. The data will be presented in three poster presentations at the Annual Meeting of the American Association for Cancer Research (AACR), being held in Washington, DC from April 1 through April 5, 2017.
Details for the poster presentations at the 2017 AACR Annual Meeting are as follows:
Title: Development
of BT1718, a novel Bicycle Drug Conjugate for the treatment of lung
cancer
Session Title: Novel
Molecular Targets 1
Abstract #: 1167/12
Date
& Time: April 3, 2017, 8:00 a.m. – 12:00 p.m. EST
Title: Bicyclic
peptides for PET imaging of MT1-MMP expressing tumors
Session
Title: Clinical Laboratory and Imagine Correlates
Abstract
#: 3719/4
Date & Time:
April 4, 2017, 8:00 a.m. – 12:00 p.m. EST
Title: BT1718,
a novel bicyclic peptide-maytansinoid conjugate targeting MT1-MMP for
the treatment of solid tumors: Design of bicyclic peptide and linker
selection
Session Title: Novel
Drug Delivery Technology
Abstract #:
5144 / 16
Date & Time: April 5,
2017, 8:00 a.m. – 12:00 p.m. EST
About Bicycle Therapeutics
Bicycle Therapeutics is
developing a new class of medicines to treat oncology and other
debilitating diseases based on its proprietary bicyclic peptide (Bicycle®)
product platform. Bicycles exhibit an affinity and exquisite
target specificity usually associated with antibodies, while a low
molecular weight delivers rapid and deep tissue penetration enabling
more efficient tumour targeting. Their peptidic nature provides a
“tuneable” pharmacokinetic half-life and a renal route of clearance,
avoiding the liver and gastrointestinal tract toxicities often seen with
other drug modalities. Bicycle Therapeutics is rapidly advancing towards
the clinic with its lead molecule, BT1718, and is collaborating in
oncology and other areas to realise the full potential of the
technology. Bicycle Therapeutics’ unique intellectual property is based
on the work initiated at the MRC Laboratory of Molecular Biology in
Cambridge, U.K., by the scientific founders of the company, Sir Gregory
Winter and Professor Christian Heinis. Bicycle Therapeutics is
headquartered in Cambridge, U.K., with a U.S. subsidiary in Cambridge,
Massachusetts. For more information, visit www.bicycletherapeutics.com.
